Latest Breaking News On - Raymondj kelleher - Page 1 : comparemela.com

Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors

Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jeff albersTillman gerngrossJonathan mandelbaumRam aiyarKorro bioVishal patelRaymondj kelleherAllison luoTriveni bioOppilan ventyxIndiana universityClinical development at ophthotech iveric bioDrug administrationClinical development for gastroenterology at progenity bioraNorthwestern universityTriveni bio inc

Garuda Therapeutics Raises $62M in Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

United kingdomAl iskandariyahRaymondj kelleherDhvanit shahGaruda therapeuticsNorthpond venturesOrbimed advisorsCormorant asset managementAisling capitalSectoral asset managementMass general brigham venturesAlexandria ventureManaging director

Arkuda Therapeutics Raises $64M in Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Raymondj kelleherGerhard koenigEli lillyHeather prestonAtlas ventureMission biocapitalArkuda therapeuticsCormorant asset managementVenture partnersSurveyor capitalPfizer venturesManaging directorArkuda boardManaging partner

Arkuda Reels in Another $64M to Disrupt Neurodegenerative Disease Treatment

Arkuda seeks to disrupt the usual progression of neurodegenerative disease with medicines developed by applying cutting-edge knowledge from the domains of lysosomal and microglial biology.

United statesRaymondj kelleherGerhard koenigArkuda therapeuticsannouncedEli lillyHeather prestonAtlas ventureTekla capital managementMission biocapitalBoston financial districtCormorant asset managementVenture partnersSurveyor capitalPfizer venturesArkuda boardRkuda reels in another 64m to disrupt neurodegenerative disease treatment

Arkuda Therapeutics Raises $64 Million Series B Financing to Advance Pipeline of Programs Targeting Lysosomal Biology to Treat Neurodegenerative Diseases

/PRNewswire/ Arkuda Therapeutics, a biotechnology company applying novel insights at the intersection of lysosomal and microglial biology to develop.

Raymondj kelleherGerhard koenigEli lillyHeather prestonAtlas ventureTekla capital managementMission biocapitalCormorant asset managementVenture partnersSurveyor capitalPfizer venturesManaging directorArkuda boardManaging partnerBruce boothArkuda therapeutics